Posted: September 4, 2014 at 6:42 pm
Ice bucket challenge don #39;t agree with stem cell research but I #39;ll donate to the charity of my choice
via YouTube Capture.
By: Robin Cuellar
See original here:
Ice bucket challenge don't agree with stem cell research but I'll donate to the charity of my choice - Video
Posted: September 4, 2014 at 2:51 pm
Congenital Hypotonia | Stem Cell Treatment | My Story
Saif and his mother, like many other families, were left with no hope after Saif was diagnosed with Benign Congenital Hypotonia, a muscle weakness disease similar to Muscular Dystrophy. Local...
By: Repair Stem Cells
Visit link:
Congenital Hypotonia | Stem Cell Treatment | My Story - Video
Posted: September 4, 2014 at 2:51 pm
(PRWEB) September 04, 2014
Local veterinarian, Dr. Kim Carlson, and her team at VCA Bay Area Veterinary Specialty in San Leandro, California are seeking candidates to participate in an investigational study of donor stem cells for dogs with osteoarthritis. The goal of this study is to determine if a single injection of donor stem cells into one or two arthritically affected joints can help reduce pain and inflammation in the treated joints.
The most common type of canine arthritis is degenerative joint disease, or osteoarthritis, affecting one out of five adult dogs in the United Sates (Canine Health Foundation, 2011). Because it is a degenerative disease, osteoarthritis continues to get worse as time goes on. The veterinary industry suggests the number of dogs being diagnosed increases each year, with many of their owners turning to anti-inflammatory and pain medications as an answer. Dr. Carlson and her team at VCA Bay Area Veterinary Specialty believe a regenerative alternative method for dogs with osteoarthritis might be of great value to many patients.
Candidates for the current investigational study must be older than nine months, weigh more than five and a half pounds, have osteoarthritis of only one or two leg joints, have had pain or lameness for at least three months, and must not have cancer. Joints that will be included in the study and injected under anesthesia include hips, stifles, shoulders, and elbows. Dogs that may be considered must be in good health and undergo a full diagnostic work up before qualifying for the study. Dogs that qualify for the study may not have had previous stem cell therapy of any kind.
Dr. Carlsons clinical interests are in utilizing minimally invasive surgical techniques to treat her patients using state-of-the-art technology. Stem cell therapy with a patients own stem cells is used extensively in her practice. For information about the study, Dr. Carlson or Sandy Tang can be reached at 510-483-7387.
About Vet-Stem, Inc. Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, and cats. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy. Ten years later Vet-Stem celebrated its 10,000th animal treated. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells.
Continue reading here:
VCA Bay Area Veterinary Specialty Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis
Posted: September 4, 2014 at 2:51 pm
Contact Information
Available for logged-in reporters only
Newswise LOS ANGELES (Sept. 4, 2014) An interdisciplinary research team in the Cedars-Sinai Biomedical Imaging Research Institute, Department of Biomedical Sciences, Regenerative Medicine Institute and Department of Surgery received a grant from the National Institutes of Health (NIH) to develop the first imaging technique used to identify biomarkers that could indicate patients have a painful, degenerative back condition.
Biomarkers are certain body substances, such as proteins or body fluids that can indicate specific health conditions. When noninvasive imaging procedures can identify exactly where the biomarkers are, researchers may alleviate the need for painful and invasive diagnostic procedures and, in the future, provide targeted, stem cell-based therapies to patients with the condition.
More than 85 percent of the United States population suffers from low back pain, much of which is caused by intervertebral disc degeneration. Disc degeneration is a progressive condition, resulting in chronic pain in the back and neck. For some patients, degeneration can occur for years before pain sets in, presenting symptoms, while others are affected almost immediately.
As described in an article in the journal Magnetic Resonance in Medicine, identifying the exact disc that is the source of pain by employing the latest imaging techniques may save patients from painful and invasive diagnostic procedures, such as procedures in which physicians inject a contrast agent or non-toxic dye into patients spinal discs.
The goal of our institute is to develop and apply novel imaging techniques that translate to clinical significance, said Debiao Li, PhD, director of the Biomedical Imaging Research Institute, corresponding author of the article and a co-principal investigator on the NIH grant. This imaging technology may allow us to do just this. By mapping a patients lower spinal region, we can identify the discs causing discomfort, which allows physicians to then treat accordingly.
In the study, investigators developed various imaging techniques using magnetic resonance imaging, or MRI, which can identify specific biomarkers to potentially provide a noninvasive diagnostic approach to intervertebral disc degeneration. The approach, which has been tested on patients and in the laboratory, enabled investigators to precisely pinpoint the origin of pain and monitor the progression of each patients condition.
With this imaging technique, investigators in the Regenerative Medicine Institute aim to generate a stem cell-based therapeutic for patients suffering from the degenerative condition.
Our research team is interested in the role of stem cells in this disease and how we can utilize these cells to regenerate the disc and turn it back into a functional tissue, said Dan Gazit, PhD, co-principal investigator on the grant and director of the Skeletal Regeneration and Stem Cell Therapy Laboratory in the Department of Surgery, the Skeletal Program in the Regenerative Medicine Institute and the Molecular and Micro Imaging Core Facility. Using this novel imaging technique, we will be able to evaluate the effect of our future stem cell therapies on back pain.
Read the original:
Researchers Developing Noninvasive Method for Diagnosing Common, Painful Back Condition
Posted: September 4, 2014 at 8:53 am
Aug. 6, 2014
Colleagues of Yoshiki Sasai, leading Japanese life science researcher, say he has taken his own life; Sasai was co-author of discredited stem cell study published in journal Nature that was retracted due to factual errors and allegations of misconduct. MORE
Journal Nature retracts two scientific papers it published that initially electrified biologists by describing easy way to make stem cells; says papers were error-filled and had not been verified by anyone else. MORE
Op-Ed article by evolutionary geneticist Svante Paabo warns against using sequenced genomes of Neanderthals to re-create Neanderthal individuals; contends from an ethical perspective such an idea should be condemned, and argues that using stem cells to create cells and tissues in test tubes for research is far more ethically defensible and technically feasible. MORE
Scientists, reporting in journal Cell Stem Cell, move step closer to goal of creating stem cells perfectly matched to a patients DNA in order to treat diseases; say they have created patient-specific cell lines for 'therapeutic cloning' out of skin cells of two adult men. MORE
Japanese research institute concludes that study published in journal Nature that was once hailed as breakthrough in creating stem cells contains fabricated and doctored images that cast doubt on its findings; singles out study's lead author Haruko Obokata, stem cell biologist, saying she had altered or misrepresented illustrations in her research papers. MORE
Japanese research institute acknowledges that study billed as breakthrough in stem cell research contained spliced image, material recycled from lead author's doctoral thesis, and other mistakes; disclosure threatens to discredit newly acclaimed researcher Haruko Obokata, whose team found that simple acid bath might turn cells in the body into stem cells; findings appeared in journal Nature. MORE
Teruhiko Wakayama, one of the authors of startling study that claimed to have found a simple way to make stem cells, says he is no longer sure of its conclusions; calls for its retraction. MORE
Study published in journal Nature finds that simple acid bath might turn out to be quicker and easier source of multipurpose stem cells than methods now in use; technique was developed by researchers at Riken Center for Developmental Biology in Kobe, Japan, and Brigham and Womens Hospital and Harvard Medical School in Boston MORE
Stem cell clinics in United States and Mexico, like Regenerative Medicine Institute in Tijuana, are offering unproven stem cell treatments for high price to desperate clients, posing challenge for scientists who are moving cautiously and seeking more data; efficacy and safety of such treatments remains in question. MORE
Read more from the original source:
Stem Cells - The New York Times
Posted: September 4, 2014 at 8:53 am
SYDNEY, Sept. 3, 2014 /PRNewswire/ -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) today announced that Graham Kelly PhD, CEO, will present at the Rodman & Renshaw 16th Annual Healthcare Conference on Wednesday, September 10th in New York. Dr. Kelly will provide an overview of the two Novogen first-in-class drug technology platforms in the field of oncology. His presentation will take place at the New York Palace Hotel and will begin at 10:25am.
About Novogen Limited
Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc, with Yale University.
Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.
Further information is available on the Company's website,www.novogen.com.
For more information please contact:
Corporate Contact
Media enquiries
Executive Chairman & CEONovogen GroupGraham.Kelly@novogen.com+61 (0) 2 9472 4100
In the USA:
Read the original post:
Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference
Posted: September 4, 2014 at 8:52 am
Piscataway, NJ (PRWEB) September 04, 2014
Dr. Young has organized a twenty-five center clinical trial network in China, Hong Kong, and Taiwan to test a new therapy for chronic spinal cord injuries using transplantation of umbilical cord blood stem cells, lithium, and intense physical rehabilitation. Phase II clinical trials have been completed and preparations are being made for Phase III trials in China, Norway, India, and the United States. Dr. Young will speak the evening of October 6th on Running Clinical Trials for Spinal Cord Injury Therapies in the US and China: Differences and Lessons Learned.
Dr. Young is the Founding Director of the W. M. Keck Center for Collaborative Neuroscience at Rutgers, the State University of New Jersey. He is a Distinguished Professor in the Department of Cell Biology and Neuroscience and also holds the Richard H. Shindell Chair in Neuroscience. The Keck Center was established in 1997 to develop effective treatments for spinal cord injuries and to move these discoveries from laboratory to human lives as rapidly as possible. The research conducted at the Center also is applicable to many other devastating conditions of the central nervous system.
Registration for the 12th NJ Symposium on Biomaterials Science is available at http://www.njbiomaterials.org/biomaterials-symposia.htm
The New Jersey Center for Biomaterials (NJCBM) was founded in 1997. Based at Rutgers, the State University of New Jersey, the center spans academia, industry, and government. Staffed by biomaterial scientists, the Center works to improve health care and quality of life by developing advanced biomedical products for tissue repair and replacement as well as the delivery of pharmaceutical agents. The Centers technologies have been translated into clinical and pre-clinical products including surgical meshes, cardiovascular stents, bone regeneration scaffolds, and ocular drug delivery systems.
Media Contact:
Louli Kourkounakis (732) 445 0488 ext. 40001 symposium(at)dls(dot)rutgers(dot)edu
Excerpt from:
Wise Young, M.D., Ph.D., Announced as 12th New Jersey Symposium on Biomaterials Science Dinner Speaker
Posted: September 4, 2014 at 8:51 am
PASCAGOULA, MS (WLOX) -
Nearly 120 doctors, nurses, technicians and other Singing River Health System employees lined up to register as a bone marrow donor in honor of their co-worker, Dr. Jeremy Simpler, who is battling cancer.
"I don't want to get emotional, but very, very devastating when we found this out because he is wonderful. He's a people person. He treated us like family," Singing River Health System Surgical Tech Patricia Taylor said.
A stranger, who gave 40 seconds to get his or her cheeks swabbed, could end up saving Simpler's life. Now, his co-workers want to repay that favor.
"Every day, we have someone looking for a match," Mattie Coburn, with the Mississippi Marrow Donor Program said.
Coburn said 70 percent of patients who need a transplant rely on the registry, because they do not have a match in their family.
There are two different ways donors are asked to donate.
"Bone marrow transplant, it is outpatient. You are put to sleep under anesthesia. We are going to go to the hip and pelvic bone with a sterile needle and syringe," Coburn said. "You are not going to feel it. We keep you overnight for observation, and release you with a Band-Aid over where the needles were. PBSC, peripheral blood stem cell, is similar to giving platelets. We draw blood, separate the cells, you get your blood back."
Three years ago, Singing River Health System Dr. Clinton Hull donated bone marrow.
"It was a really good feeling," Hull said. "The last communication I had through the bone marrow service was the patient had returned to their daily activities and living, so that makes me feel really good."
Originally posted here:
Co-workers honor doctor by registering as bone marrow donors
Posted: September 4, 2014 at 8:50 am
PUBLIC RELEASE DATE:
3-Sep-2014
Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair
Putnam Valley, NY. (Sept. 3, 2014) A team of researchers from Korea and Canada have found that transplantation of B10 cells (a stable immortalized human bone marrow derived mesenchymal stem cell line; B10 hMSC) directly into the bladder wall of mice modeled with spinal cord injury (SCI) helped inhibit the development of bladder fibrosis and improved bladder function by promoting the growth of smooth muscle cells in the bladder.
The study will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-CT-1227_Lee.
Spinal cord injury (SCI) can cause severe lower urinary tract dysfunction and conditions such as overactive bladder, urinary retention and increased bladder thickness and fibrosis. HMSCs, multipotent cells that can differentiate into a variety of cell types, including bone cells, cartilage cells, and fat cells, have been transplanted into injured spinal cords to help patients regain motor function.
In this study, mice receiving the B10 hMSCs injected directly into the bladder wall experienced improved bladder function while an untreated control group did not.
"Human MSCs can secrete growth factors," said study co-author Seung U. Kim of the Division of Neurology at the University of British Columbia Hospital, Vancouver, Canada. "In a previous study, we showed that B 10 cells secrete various growth factors including hepatocyte growth factor (HGF) and that HGF inhibits collagen deposits in bladder outlet obstructions in rats more than hMSCs alone. In this study, the SCI control group that did not receive B10 cells showed degenerated spinal neurons and did not recover. The B10-injected group appeared to have regenerated bladder smooth muscle cells."
Four weeks after the onset of SCI, the treatment group received the B10 cells transplanted directly into the bladder wall. To track the transplanted B10 cells via magnetic resonance imaging (MRI), the researchers labeled them with fluorescent magnetic particles.
"HGF plays an essential role in tissue regeneration and angiogenesis and acts as a potent antifibrotic agent," explained Kim.
See original here:
Transplanted stem cells help prevent bladder fibrosis after spinal cord injury
Posted: September 4, 2014 at 8:49 am
Los Angeles, California (PRWEB) September 03, 2014
Stem Cell technology is the future; looking younger and better without plastic surgery is here now. Stem Cell Beautys debut product line StemLife is spearheading the current beauty renaissance. Among websites that provide stem cell beauty products, Stem Cell Beauty is in a league of its own.
Science is always advancing, why shouldn't your beauty products? questions Albert Faleski, Director of Operations at StemCellBeauty.com.
Most products on the shelves are outdated, whereas we take a different approach to find a formula that works with your body, reinvigorating your own stem cells to provide actual results.
The science behind StemLife is nothing short of groundbreaking. Its trademarked FixT Technology was achieved through reverse engineering to understand how the body maintains and heals itself with our own endogenous combinations of adult stem cells. With this knowledge they developed a means to mimic the natural stem cell processes in our body. Unlike other beauty brands, StemLife uses specific combinations of stem cell types, each cultured under specific state-dependent conditions, using cell types and states that are ideal for the particular tissue. It then creates a set of molecules from multiple stem cell types that is complete and fully formed, rendering maximum benefit and efficiency. This approach of stem cell skin care is extremely unique.
Other leading stem cell-based beauty companies use simpler technology where one stem cell type is chosen to make their molecules. This one-size fits all approach is not efficient and lacks the complexity of StemLifes FixT technology. Some companies mash the cells without allowing their molecules to fully process, which again leads to underachieving results. Many of the largest companies have made no attempt to use new science to formulate better products, providing their customers with over-priced serums proven to be archaic.
StemLifes cutting edge formula is shaping the future of hair regrowth as well, providing an ultramodern solution to those looking to slow the hands of time. Their most popular product, The Advanced Hair Treatment for Women, is essentially the hidden gem the world has been waiting for.
Its popularity stems back to the fact that it actually works. Faleski explained.
Were not big on gimmicks. We prefer showing our customer actual people who have had actual results with our products. After seeing life-changing hair growth with their own eyes, we are confident new customers will try it and have amazing results of their own. The Advanced Hair Treatment for Women is an incredible product that sells itself.
StemLifes most interesting product to date is the Natural Lash & Brow Lash Extend. This product boasts ingredients that are formulated to generate eyelash growth. In a market where eyelash extensions have been the go-to fix for longer lashes, being able to naturally grow them is a revolutionary concept.
Follow this link:
Stem Cell Beauty: The Online Shop Revolutionizing the Beauty Industry
